secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-048684
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics secures standby direct license to Kobe University patents for base editing
--------------------------------------------------------------------------------

- Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.
- If Kobe-Bio Palette license terminates (barring Beam-caused breach), Kobe grants Beam an exclusive direct license.
- Beam will pay Kobe the same amounts it would have paid Bio Palette under the original sublicense.
- Beam assumes prosecution and maintenance costs for Kobe patents after the effective time.
- Standby license covers the same scope as Beam's current sublicense from Bio Palette.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526048684/0001193125-26-048684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526048684/beam-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-048684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer